Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.56

€1.56

-
-
-
-
 
12.02.24 / Stuttgart Stock Exchange WKN: A2DL9L / Name: Arix Bioscience / Stock / Holding Companies / Small Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Arix Bioscience

sharewise wants to provide you with the best news and tools for Arix Bioscience, so we directly link to the best financial data sources.

News

Scheme Effective
Scheme Effective
Scheme Effective
Suspension of Trading in Shares
Suspension of Trading in Shares
Suspension of Trading in Shares
Transaction Update
Transaction Update
Transaction Update
Results of First General Meeting
Results of First General Meeting
Results of First General Meeting
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Update on the Scheme and Publication of Notice of Second General Meeting
Update on the Scheme and Publication of Notice of Second General Meeting
Update on the Scheme and Publication of Notice of Second General Meeting
Update on the Scheme and Resignation of Directors
Update on the Scheme and Resignation of Directors
Update on the Scheme and Resignation of Directors
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Financial update on Harpoon Therapeutics acquisition by Merck (MSD)
Unaudited NAV for December 2023
Unaudited NAV for December 2023
Unaudited NAV for December 2023
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
Publication of Circular and RTW Bio Prospectus
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
Update regarding timing of Proposed Scheme of Reconstruction
Unaudited NAV for November 2023
Unaudited NAV for November 2023
Unaudited NAV for November 2023
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
Unaudited NAV for October 2023
Unaudited NAV for October 2023
Unaudited NAV for October 2023
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
PDMR Notification & Director Shareholding
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Portfolio company Harpoon Therapeutics announces up to $150 million private placement
Unaudited NAV for September 2023
Unaudited NAV for September 2023
Unaudited NAV for September 2023